Presently, the U.S. Food and Drug Administration (FDA) have authorized the consumption of some mAbs including: cemiplimab (Libtayo), pembrolizumab (Keytruda), avelumab (Bavencio), atezolizumab (Tecentriq), durvalumab (Imfinzi), and nivolumab (Opdivo) for targeting PD‐1 and PD‐L1 in cancer immunotherapy.78, 79, 80. This evidence concerns the gene CD274 and cancer.